Indole-3-propionic acid for multiple sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests an oral supplement called indole-3-propionic acid to see if it can help people with relapsing-remitting multiple sclerosis (RRMS). It involves taking the supplement daily and having regular MRI scans to monitor your MS.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with relapsing-remitting multiple sclerosis (RRMS).
- You are currently being treated and monitored for MS.
- You speak and read Danish.
- You do not have Crohn's disease, ulcerative colitis, or any active cancer.
- You have no metal implants or devices that prevent an MRI.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new oral medication called Rocbrutinib for people with relapsing-remitting multiple sclerosis (RRMS). The drug targets a protein that may help reduce the immune system's attack on the brain and spinal cord. The trial will check if the medication can reduce new brain lesions and slow down disability progression.
This trial tests a natural supplement called indole-3-propionic acid in healthy adults. Researchers want to see how your body responds to it and how safe it is.
This study tests whether adding a probiotic supplement to your usual MS treatment (or to no treatment) can help manage relapsing-remitting multiple sclerosis. It aims to see if the probiotic is safe and beneficial as an add-on therapy.
This study tests an experimental drug called RO7121932 in people with multiple sclerosis. The goal is to see how safe it is and how the body processes it. It might help by offering a new way to manage the condition.
This study uses a special PET-MRI scan to look at brain inflammation in people with relapsing-remitting multiple sclerosis (RRMS). It may help researchers understand how inflammation changes when starting a stronger MS treatment.
This study tests whether a medicine that targets a specific brain inflammation marker (TSPO) can help in people with certain types of multiple sclerosis. It focuses on safety and whether the target can be measured and influenced during treatment.
Hear when a new Relapsing Remitting Multiple Sclerosis (RRMS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.